Valeant Pharma (VRX) “Buy” Rating Kept by Analysts at Jefferies; The Target Price per Share Given is $18.0000, VIEW SYSTEMS (VSYM) Shorts Raised By 50%

June 9, 2017 - By Michael Collier

VIEW SYSTEMS INCORPORATED (OTCMKTS:VSYM) had an increase of 50% in short interest. VSYM’s SI was 12,000 shares in June as released by FINRA. Its up 50% from 8,000 shares previously. With 193,100 avg volume, 0 days are for VIEW SYSTEMS INCORPORATED (OTCMKTS:VSYM)’s short sellers to cover VSYM’s short positions. It closed at $0.0027 lastly. It is down 0.00% since June 9, 2016 and is . It has underperformed by 16.70% the S&P500.

Among 24 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 5 have Buy rating, 3 Sell and 16 Hold. Therefore 21% are positive. Valeant Pharmaceuticals Intl has $310 highest and $9 lowest target. $75’s average target is 500.00% above currents $12.5 stock price. Valeant Pharmaceuticals Intl had 95 analyst reports since July 21, 2015 according to SRatingsIntel. Rodman & Renshaw initiated Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rating on Tuesday, February 16. Rodman & Renshaw has “Buy” rating and $150 target. IBC reinitiated the stock with “Sector Perform” rating in Monday, November 30 report. The firm has “Buy” rating by Rodman & Renshaw given on Monday, April 11. The firm earned “Outperform” rating on Wednesday, November 11 by RBC Capital Markets. The firm has “Sector Perform” rating given on Wednesday, May 10 by RBC Capital Markets. The company was maintained on Monday, November 14 by Deutsche Bank. As per Wednesday, March 16, the company rating was maintained by Jefferies. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) earned “Equal Weight” rating by Barclays Capital on Friday, February 10. The company was downgraded on Tuesday, March 15 by Piper Jaffray. The stock has “Underperform” rating by Wells Fargo on Friday, February 19.

Investors sentiment decreased to 0.78 in Q4 2016. Its down 0.10, from 0.88 in 2016Q3. It dived, as 82 investors sold Valeant Pharmaceuticals Intl Inc shares while 87 reduced holdings. 49 funds opened positions while 82 raised stakes. 193.03 million shares or 13.22% less from 222.43 million shares in 2016Q3 were reported. 28,100 are held by Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Inv Management. The United Kingdom-based Legal General Group Incorporated Public Ltd Co has invested 0.02% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Aviva Public Ltd Com has invested 0.02% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). The Connecticut-based Silver Point Cap Limited Partnership has invested 0.89% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Quantitative Mgmt Ltd Liability Corp holds 0.02% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 42,000 shares. Winfield Assocs, a Ohio-based fund reported 90 shares. Alps Incorporated invested 0% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Hexavest owns 264,677 shares. Stifel Corp has 159,270 shares. Columbus Hill Capital Lp reported 685,000 shares. Capstone Asset Mngmt stated it has 0.01% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Citigroup Inc has invested 0% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Continental Ltd Liability Com holds 0.46% or 117,300 shares in its portfolio. Invesco reported 58,445 shares. Cibc World Markets owns 3.59 million shares.

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has market cap of $4.67 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It currently has negative earnings. It operates through two divisions: Developed markets and Emerging markets.

Since December 12, 2016, it had 4 buys, and 2 insider sales for $217.81 million activity. The insider Pershing Square Capital Management – L.P. sold 18.11M shares worth $199.26M. Herendeen Paul bought $257,280 worth of stock. DE SCHUTTER RICHARD U bought $278,000 worth of stock or 20,000 shares. $73,650 worth of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares were bought by Ross Thomas W. Sr.. Shares for $32.47M were bought by ValueAct Holdings – L.P. on Tuesday, March 14.

About 22.19M shares traded. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 48.51% since June 9, 2016 and is downtrending. It has underperformed by 65.21% the S&P500.

View Systems, Inc. develops, produces and markets computer software and hardware systems for security and surveillance applications. The company has market cap of $840,250. The Firm offers digital video recorder technology. It currently has negative earnings. It is engaged in developing interfaces with various technologies, such as facial recognition; access control cards and control devices, such as magnetic locks and alarms, and other security devices.